<DOC>
	<DOC>NCT01327924</DOC>
	<brief_summary>This study is conducted in Europe. The purpose of this study is to assess the impact on daily life for children new to using a growth hormone injection device.</brief_summary>
	<brief_title>Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Growth hormone (GH) treatment naïve subjects for whom it has been decided to initiate GH treatment prior to enrollment into the study Subjects who receive Norditropin NordiFlex® according to the SPC Known or suspected allergy to study product(s) or related products Child and/or parent unable to give consent or fill out the questionnaires The receipt of any investigational medicinal product within 3 months prior to this study Suffer from a lifethreatening disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>